157. スタージ・ウェーバー症候群
［臨床試験数：8，薬物数：11（DrugBank：4），標的遺伝子数：5，標的パスウェイ数：62］
Searched query = "Sturge-Weber syndrome", "Síndrome de Sturge-Weber"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04447846 (ClinicalTrials.gov) | October 14, 2019 | 10/10/2019 | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Recruiting | 3 Years | 50 Years | All | 10 | Phase 2 | United States |
| 2 | NCT03047980 (ClinicalTrials.gov) | January 2017 | 2/2/2017 | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Sirolimus | Anne Comi, MD | Children's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 3 Years | 31 Years | All | 10 | Phase 2;Phase 3 | United States |
| 3 | NCT02332655 (ClinicalTrials.gov) | December 2014 | 5/1/2015 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Active, not recruiting | 1 Month | 45 Years | All | 5 | Phase 1;Phase 2 | United States |
| 4 | NCT01997255 (ClinicalTrials.gov) | April 2014 | 15/11/2013 | Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) | An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome | Sturge Weber Syndrome | Drug: Everolimus | Baylor College of Medicine | Novartis Pharmaceuticals | Withdrawn | 2 Years | 18 Years | Both | 0 | Phase 2 | United States |
| 5 | NCT01533376 (ClinicalTrials.gov) | February 2012 | 11/2/2012 | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Sturge Weber Syndrome;Port-wine Mark | Drug: Timolol;Drug: Preservative free artificial tear gel. | Wills Eye | University of Medicine and Dentistry of New Jersey | Terminated | 2 Years | 10 Years | All | 3 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2010-024078-20-ES (EUCTR) | 11/05/2011 | 15/12/2010 | Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber | Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber | Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber. MedDRA version: 13;Level: PT;Classification code 10042265;Term: Síndrome de Sturge-Weber | Product Name: Rapamicina tópica al 1% y excipiente INN or Proposed INN: crema de rapamicina al 1% y excipientes Product Name: Crema placebo (excipiente) INN or Proposed INN: Crema placebo (excipiente) | Instituto Científico y Tecnológico de Navarra | NULL | Not Recruiting | Female: yes Male: yes | Spain | ||||
| 7 | NCT02080624 (ClinicalTrials.gov) | January 2011 | 18/4/2013 | Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome | Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome. | Sturge- Weber Syndrome | Drug: Drug: Topical Rapamycin | Clinica Universidad de Navarra, Universidad de Navarra | NULL | Completed | 16 Years | 65 Years | Both | 23 | Phase 2 | Spain |
| 8 | NCT00639730 (ClinicalTrials.gov) | May 2006 | 14/3/2008 | Use of the Atkins Diet for Children With Sturge Weber Syndrome | Use of the Atkins Diet for Children With Sturge Weber Syndrome | Epilepsy;Sturge Weber Syndrome | Dietary Supplement: modified Atkins diet | Johns Hopkins University | Vascular Birthmarks Foundation | Completed | 2 Years | 18 Years | Both | 5 | Phase 1 | United States |